Hypometabolism of the posterior parietal cortex in Parkinson’s disease with mild cognitive impairment predicts the conversion to dementia: 5-year longitudinal observations
Objective: To investigate the neuroimaging marker that predict the conversion of mild cognitive impairment (MCI) to dementia in Parkinson’s disease (PD) patients. Background: Patients with…Relationships between specific subtypes of mild cognitive impairment and grey matter atrophy in Parkinson’s disease
Objective: Our aim was to investigate grey matter (GM) atrophy patterns in Parkinson’s disease patients with normal cognation (PD-NC) or with mild cognitive impairment（PD-MCI）using voxel…In vivo MRI signatures of hippocampal subfield pathology in patients with Parkinson’s disease and psychosis
Objective: To study the role of hippocampal subfield pathology in the genesis of psychotic symptoms in patients with Parkinson's disease (PD) by comparing the volumes…Alterations of cortical metabotropic glutamate receptor-mediated signaling in patients with Parkinson’s disease
Objective: To evaluate expression of brain metabotropic glutamatergic receptor 5 and the relationship with clinical measures in Parkinson’s disease patients. Background: Metabotropic glutamate receptor 5…Amyloid PET and cognition in Parkinson’s disease
Objective: To investigate the relationship between cerebral amyloid accumulation and cognition in Parkinson’s disease (PD). Background: The neuropathology underlying the development of dementia in Parkinson’s…Clinical and imaging progression in the PARS cohort: Results from 6 years of observation
Objective: The goal of the Parkinson Associated Risk Syndrome (PARS) study is to explore the clinical and biomarker trajectory of individuals in the pre-motor phase…Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP): Results of the SIAXI study
Objective: The pivotal double-blind, randomised Phase III SIAXI study (NCT02091739), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U for sialorrhea. Co-primary endpoints…Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder
Objective: Study the relationship between RBD and other symptoms of PD. Background: Rapid eye movement sleep behavior disorder (RBD) and Parkinson’s disease (PD) are two…Striatal dopamine transporter availability changes reflect gastrointestinal dysautonomia severity in early Parkinson’s disease
Objective: To test the hypothesis that constipation and gastrointestinal (GI) dysautonomia may be correlated with nigrostriatal dopaminergic (DA) dysfunction in PD. Background: Constipation is a…Sensory signs and neuropathic pain in advanced Parkinson’s disease under levodopa treatment
Objective: To evaluate whether patients affected by Parkinson’s disease (PD) under levodopa/carbidopa intestinal gel (LCIG) therapy have alterations in sensory symptoms and signs and/or painful…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.